Will cancer stem cells provide more effective biomarkers?

Area of Science:

• Oncology
• Cancer Biology
• Translational Medicine

Background:

• Cancer stem cells (CSCs) are a rare tumor cell subpopulation driving tumor initiation and relapse.
• Preclinical data highlight CSCs as critical targets for cancer therapy, with several anti-CSC treatments in development.

Purpose of the Study:

• To review the role of CSCs in patient outcomes.
• To discuss the need for, challenges in developing, and potential of CSC biomarkers for clinical application.

Main Methods:

• Literature review of experimental evidence on CSCs and patient outcomes.
• Analysis of current anti-CSC therapeutic strategies and biomarker development.

Main Results:

• CSCs are implicated in tumor initiation, metastasis, and therapeutic resistance.
• Biomarkers are needed to assess treatment response and patient prognosis in CSC-targeted therapies.

Conclusions:

• CSCs are pivotal in cancer progression and recurrence, necessitating targeted therapies.
• Development of reliable CSC biomarkers is essential for advancing clinical treatments and improving patient management.